Cantharidin and Occlusion in Verruca Epithelium

Summary

This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts.

Conditions

• Common Wart
• Warts Hand
• Warts
• Papillomavirus Infections
• DNA Virus Infections
• Skin Diseases, Viral
• Skin Diseases, Infectious
• Skin Diseases
• Virus Diseases
• Tumor Virus Infections
• Verruca Vulgaris
• Verruca

Interventions

COMBINATION_PRODUCT

VP-102 Cantharidin topical film forming solution

VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.

COMBINATION_PRODUCT

VP-102 Cantharidin, topical film forming solution

VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.

Sponsors & Collaborators

• Instat Consulting, Inc.

  collaborator OTHER

• Paidion Research, Inc.

  collaborator INDUSTRY

• BioClinica, Inc.

  collaborator INDUSTRY

• ALMAC Clinical Services

  collaborator INDUSTRY

• Verrica Pharmaceuticals Inc.

  lead INDUSTRY

Principal Investigators

• Adnan Nasir, MD · Cohort 1: Wake Dermatology

• Scott Guenthner, MD · Cohort 2: Indiana Clinical Trials Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

2 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-03-27

Primary Completion

2019-05-16

Completion

2019-07-15

FDA Drug

Yes

FDA Device

Yes

Countries

• United States

Study Locations